IMAGENE Co., Ltd.

CanvOI Oncology Intelligence (OI) foundation model is designed to decode cancer from biopsy images and drive cancer research forward MIAMI and AUSTIN, Texas, Sept. 10, 2024 /PRNewswire/ -- Oracle and Imagene, a pioneer in AI-based precision oncology, today announced CanvOI, a state-of-the-art pan-cancer foundation model designed to facilitate innovative research and development in the digital pathology and oncology space. Running on Oracle Cloud Infrastructure (OCI), CanvOI captures the complex features and patterns within biopsy images, providing valuable oncology intelligence that could improve the way cancer is diagnosed and treated around the world. CanvOI delivers a robust vision data backbone for the development of downstream applications in oncology research, including predicting treatment responses, discovering biomarkers, assessing disease prognosis, and identifying pathological features with state-of-the-art results, outperforming leading foundation models built for digital pathology. For AI inference computation and to process data at scale, Imagene partnered with Oracle to run CanvOI on OCI, taking advantage of OCI Supercluster and OCI AI Infrastructure technology. "To transform cancer research, Imagene did what countless other leading AI startups have done – it turned to Oracle's Gen2 AI infrastructure, which delivers the scale and performance required to power the world's largest AI models and help solve humanity's most difficult challenges," said Larry Ellison, Oracle Chairman and CTO. "With CanvOI running on Oracle Cloud Infrastructure, Oracle and Imagene are providing scientists with new weapons in the fight against mankind's deadliest adversary, cancer." "The next decade holds immense potential for breakthroughs in cancer research driven by Artificial Intelligence," said Dean Bitan, Co-founder and CEO, Imagene. "We designed CanvOI to inspire researchers to dare to explore beyond. This is a pivotal milestone in the fight against this complex and devastating disease. By opening doors for innovative research, we aim to fundamentally change the future of cancer care." CanvOI, a 1.1 billion parameters foundation model, was pre-trained on a diverse dataset including more than 630,000 tissue images from over 100 sites, covering more than 40 major body organs and tissue types. By applying a new approach to digital pathology foundation models and pushing computational demands differently, CanvOI has achieved industry-leading performance across various cancer-related tasks. Its ability to perform effectively, even with minimal labeled data, is crucial in the biomedical space, where data availability can be challenging. CanvOI is the cornerstone of Imagene's new OISuite, a platform that supports researchers and diagnostics developers to explore a wide range of questions to conduct in-depth research independently, alleviating the need for AI expertise and extensive data acquisition. OISuite enables rapid discoveries while delivering the highest standards of data privacy and security. "CanvOI transforms our approach to healthcare and disease understanding," said Dr. David Agus, Founding Director and Co-CEO, Ellison Institute of Technology and Imagene board member. "By providing access to comprehensive oncology intelligence in the cloud, it enables researchers to develop answers quicker and more efficiently. EIT is committed to leveraging CanvOI to propel groundbreaking innovations in our research that improve patient lives. This technology marks a new era of cancer research that pushes us closer to a future where cancer is a manageable condition." Additional Resources CanvOI scientific paper, including benchmarks About Imagene Imagene is a pioneering company in AI-based precision oncology, dedicated to decoding cancer using biopsy images. Our mission is to unlock the power of Oncology Intelligence to transform cancer research and diagnostics. Imagene's OISuite, powered by our state-of-the-art pan-cancer vision foundation model, enables the development of diverse applications and accelerates discoveries in oncology. LungOI, our AI-based NSCLC multi-gene test, was developed using our foundation model and provides rapid biomarker profiling, facilitating informed clinical decisions. About Oracle Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at . Trademarks Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing. SOURCE Oracle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Imagene will also present its poster, "Image-based detection of FGFR3-fusion in urothelial bladder cancer"CHICAGO, June 01, 2022 (GLOBE NEWSWIRE) -- Imagene AI, an emerging leader in the field of AI-based precision medicine for cancer, today announced that it will demonstrate its molecular and spatial intelligence platform at the 2022 American Society of Clinical Oncology (ASCO) conference. Imagene’s deep learning models have been shown to detect a wide range of cancer biomarkers in real time, using only a digitally scanned Hematoxylin and Eosin (H&E) image. Imagene’s molecular classifier platform currently detects 28 cancer biomarkers, spanning seven organs, including lung, thyroid, breast, ovary, CNS, bladder, and hematologic malignancies. When compared to gold standard genomic testing methods, Imagene’s validation demonstrated, on average, sensitivity of 94.8%, greater than 90% specificity, and an AUC over 0.95. Imagene has demonstrated the capability to identify a spectrum of alterations, including mutations (e.g., EGFR), fusions and other structural variants (e.g., NTRK), differential gene expression (e.g., HER2), and cancer signatures (e.g., HRD). Imagene leadership team will offer individual presentations in its ASCO booth, #2086, June 4-6 during exhibiting hours (9:00 a.m. to 5:00 p.m. CDT) at McCormick Place in Chicago. “Imagene’s deep-learning technology, which continues to detect a growing number of cancer biomarkers in real time using only an H&E image, has the potential to truly democratize access to precision medicine, allowing for both improved quality of care and stratification of patients into clinical trials,” said Dean Bitan, co-founder and CEO at Imagene. “We look forward to participating at ASCO and demonstrating how our technology unlocks valuable information to support oncologists and pathologists, as well as drug developers and researchers.” As example of Imagene’s biomarker detection capabilities, its abstract, “Image-based detection of FGFR3-fusion in urothelial bladder cancer,” was accepted for ASCO poster presentation (Abstract No. 3072; Poster No. 64), June 5, at 4:00 CDT. The FGFR3 classification model was validated on a cohort of 150 patients from 19 different medical centers. FGFR3 is a prognostic, predictive, and therapeutic target in urothelial bladder cancer, directing targeted treatment such as BALVERSA® (erdafitinib) in locally advanced or metastatic urothelial carcinoma. The initial research shows that FGFR3 alteration (mutations and fusions) accounts for up to 80% of the cases (depending on grade and stage). Screening these patients using an image-based solution has potential to dramatically speed-up diagnosis time and improve diagnostic accuracy, leading to well-timed, personalized treatment. ABOUT IMAGENE AI Imagene AI is a precision oncology diagnosis company. Its molecular and spatial intelligence platform delivers real-time biomarker reports using only digitized biopsy images, leading to faster diagnosis and better identification of treatment for patients. Its multidisciplinary team is composed of a diverse group of experts from the fields of science, clinical, and deep learning. Imagene collaborates with top-tier medical centers and pharmaceutical companies worldwide, making therapeutic decisions for cancer more accurate and accessible, profiling patients for clinical trials, and accelerating the drug development process. For more information, visit Imagene-AI.com. The mentioned products are currently used for research purposes only and subject to regulatory clearances in the applicable markets. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bd71b203-3561-4d86-b8db-7a4a93e513c6